Heidelberg Pharma Future Growth
Future criteria checks 2/6
Heidelberg Pharma's earnings are forecast to decline at 33% per annum while its annual revenue is expected to grow at 42.2% per year. EPS is expected to decline by 34.6% per annum.
Key information
-33.0%
Earnings growth rate
-34.6%
EPS growth rate
| Biotechs earnings growth | 34.9% |
| Revenue growth rate | 42.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Oct 2024 |
Recent future growth updates
Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16
Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17
We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 11/30/2026 | 13 | -39 | N/A | N/A | 1 |
| 11/30/2025 | 12 | -46 | N/A | N/A | 2 |
| 11/30/2024 | 10 | -22 | N/A | N/A | 1 |
| 8/31/2024 | 4 | -19 | -30 | -30 | N/A |
| 5/31/2024 | 10 | -13 | -33 | -32 | N/A |
| 2/29/2024 | 9 | -18 | -34 | -34 | N/A |
| 11/30/2023 | 10 | -20 | -35 | -34 | N/A |
| 8/31/2023 | 10 | -22 | -35 | -34 | N/A |
| 5/31/2023 | 11 | -27 | -35 | -34 | N/A |
| 2/28/2023 | 20 | -19 | -14 | -13 | N/A |
| 11/30/2022 | 19 | -20 | -9 | -9 | N/A |
| 8/31/2022 | 17 | -21 | -9 | -8 | N/A |
| 5/31/2022 | 13 | -22 | -7 | -6 | N/A |
| 2/28/2022 | 2 | -27 | -28 | -27 | N/A |
| 11/30/2021 | 2 | -26 | -28 | -27 | N/A |
| 8/31/2021 | 2 | -25 | -25 | -23 | N/A |
| 5/31/2021 | 7 | -22 | -24 | -23 | N/A |
| 2/28/2021 | 7 | -20 | -21 | -20 | N/A |
| 11/30/2020 | 9 | -18 | -19 | -18 | N/A |
| 8/31/2020 | 10 | -17 | -18 | -17 | N/A |
| 5/31/2020 | 7 | -15 | -12 | -11 | N/A |
| 2/29/2020 | 8 | -12 | -11 | -10 | N/A |
| 11/30/2019 | 7 | -10 | -10 | -9 | N/A |
| 8/31/2019 | 7 | -10 | -10 | -9 | N/A |
| 5/31/2019 | 6 | -11 | -12 | -12 | N/A |
| 2/28/2019 | 4 | -12 | -11 | -10 | N/A |
| 11/30/2018 | 4 | -12 | -11 | -10 | N/A |
| 8/31/2018 | 4 | -11 | -11 | -10 | N/A |
| 5/31/2018 | 3 | -11 | N/A | -8 | N/A |
| 2/28/2018 | 2 | -11 | N/A | -9 | N/A |
| 11/30/2017 | 2 | -11 | N/A | -8 | N/A |
| 8/31/2017 | 2 | -10 | N/A | -7 | N/A |
| 5/31/2017 | 2 | -8 | N/A | -8 | N/A |
| 2/28/2017 | 2 | -7 | N/A | -7 | N/A |
| 11/30/2016 | 2 | -6 | N/A | -7 | N/A |
| 8/31/2016 | 2 | -7 | N/A | -6 | N/A |
| 5/31/2016 | 2 | -7 | N/A | -5 | N/A |
| 2/29/2016 | 2 | -7 | N/A | -5 | N/A |
| 11/30/2015 | 3 | -7 | N/A | -5 | N/A |
| 8/31/2015 | 3 | -5 | N/A | -4 | N/A |
| 5/31/2015 | 5 | -3 | N/A | -3 | N/A |
| 2/28/2015 | 4 | -4 | N/A | -4 | N/A |
| 11/30/2014 | 4 | -6 | N/A | -7 | N/A |
| 8/31/2014 | 7 | -5 | N/A | -7 | N/A |
| 5/31/2014 | 9 | -6 | N/A | -10 | N/A |
| 2/28/2014 | 11 | -6 | N/A | -12 | N/A |
| 11/30/2013 | 14 | -5 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HPHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HPHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HPHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HPHA's revenue (42.2% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: HPHA's revenue (42.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HPHA's Return on Equity is forecast to be high in 3 years time